DiaMedica Therapeutics Inc. (DMAC)
DMAC Stock Price Chart
Explore DiaMedica Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze DMAC price movements and trends.
DMAC Company Profile
Discover essential business fundamentals and corporate details for DiaMedica Therapeutics Inc. (DMAC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Aug 2012
Employees
27.00
Website
https://www.diamedica.comCEO
Dietrich John Pauls
Description
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DMAC Financial Timeline
Browse a chronological timeline of DiaMedica Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.19, while revenue estimate is $13.50m.
Earnings released on 6 May 2026
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%.
Earnings released on 30 Mar 2026
EPS came in at -$0.17 matching the estimated -$0.17.
Earnings released on 12 Nov 2025
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%.
Earnings released on 12 Aug 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 13 May 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 17 Mar 2025
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%.
Earnings released on 13 Nov 2024
EPS came in at -$0.15 matching the estimated -$0.15.
Earnings released on 7 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%.
Earnings released on 8 May 2024
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%.
Earnings released on 19 Mar 2024
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $30.84m .
Earnings released on 13 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.14 by +14.29%.
Earnings released on 14 Aug 2023
EPS came in at -$0.16 surpassing the estimated -$0.22 by +27.27%.
Earnings released on 15 May 2023
EPS came in at -$0.20 falling short of the estimated -$0.16 by -25.00%.
Earnings released on 28 Mar 2023
EPS came in at -$0.14 matching the estimated -$0.14.
Earnings released on 9 Nov 2022
EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $76.00k .
Earnings released on 10 Aug 2022
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $13.00k .
Earnings released on 4 May 2022
EPS came in at -$0.13 surpassing the estimated -$0.20 by +35.00%.
Earnings released on 14 Mar 2022
EPS came in at -$0.10 surpassing the estimated -$0.16 by +37.50%.
Earnings released on 10 Nov 2021
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%.
Earnings released on 11 Aug 2021
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%.
DMAC Stock Performance
Access detailed DMAC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
